
Dimitrios Sagris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/793185/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anticoagulation for stroke prevention after embolic stroke of undetermined source of presumably cardiac source: The sail to Ithaca. European Journal of Internal Medicine, 2022, 95, 42-43.	2.2	0
2	Immunity, Vascular Aging and Stroke. Current Medicinal Chemistry, 2022, 29, 5510-5521.	2.4	7
3	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. European Journal of Internal Medicine, 2022, 101, 41-48.	2.2	12
4	Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover AtrialÂFibrillation in Patients With IschemicÂStroke. Journal of the American College of Cardiology, 2022, 79, 1369-1381.	2.8	17
5	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke, 2022, 53, 2620-2627.	2.0	28
6	Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity. Lancet Regional Health - Europe, The, 2022, 17, 100395.	5.6	3
7	Long-Term Cardiac Monitoring After Embolic Stroke of Undetermined Source: Search Longer, Look Harder. American Journal of Medicine, 2022, 135, e311-e317.	1.5	5
8	Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 1879-1887.	3.4	5
9	Sinus rhythm restoration and improved outcomes in patients with acute ischemic stroke and in-hospital paroxysmal atrial fibrillation. European Stroke Journal, 2022, 7, 421-430.	5.5	5
10	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. International Journal of Stroke, 2021, 16, 738-750.	5.9	11
11	Carotid Atherosclerosis and Patent Foramen Ovale in Embolic Stroke of Undetermined Source. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105409.	1.6	11
12	Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source. Thrombosis and Haemostasis, 2021, 121, 361-365.	3.4	7
13	Atrial fibrillation and cognitive decline: it takes more than an irregular heart beat, to beat the brain. Age and Ageing, 2021, 50, 1891-1893.	1.6	1
14	Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation. Annals of Medicine, 2021, 53, 1613-1620.	3.8	9
15	Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. European Journal of Internal Medicine, 2021, 85, 130-132.	2.2	7
16	Statin treatment and outcomes after embolic stroke of undetermined source. Internal and Emergency Medicine, 2021, 16, 1261-1266.	2.0	5
17	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	2.0	7
18	Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature. Frontiers in Neurology, 2021, 12, 666086.	2.4	10

DIMITRIOS SAGRIS

#	Article	IF	CITATIONS
19	Validation of the AF-ESUS score to identify patients with embolic stroke of undetermined source and low risk of device-detected atrial fibrillation. European Journal of Internal Medicine, 2021, 89, 135-136.	2.2	12
20	COVIDâ€19 and ischemic stroke. European Journal of Neurology, 2021, 28, 3826-3836.	3.3	55
21	Machine-Learning-Derived Model for the Stratification of Cardiovascular risk in Patients with Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106018.	1.6	4
22	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series. Frontiers in Neurology, 2021, 12, 727403.	2.4	1
23	Atrial Highâ€Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e022487.	3.7	17
24	Response by Sagris et al to Letter Regarding Article, "Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis― Stroke, 2020, 51, e39.	2.0	0
25	Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. European Journal of Internal Medicine, 2020, 79, 31-36.	2.2	8
26	Characteristics and outcomes of Embolic Stroke of Undetermined Source according to stroke severity. International Journal of Stroke, 2020, 15, 866-871.	5.9	6
27	Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. Neurology, 2020, 95, e499-e507.	1.1	7
28	Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. Stroke, 2019, 50, 3135-3140.	2.0	16
29	20-year trends of characteristics and outcomes of stroke patients with atrial fibrillation. International Journal of Stroke, 2018, 13, 707-716.	5.9	8
30	Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack. Stroke, 2018, 49, 412-418.	2.0	99